This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
references
Lindstrom J. The structures of neuronal nicotinic receptors. In: Clementi F, Fornasari D, Gotti C (eds) Neuronal Nicotinic Receptors, Handbook of Experimental Pharmacology, vol 144. New York: Springer, 2000, pp 101–162.
McGehee DS, Role LW. Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurones. Annu Rev Physiol 1995;57:521–546.
Karlin A. Emerging structure of the nicotinic acetylcholine receptors. Nat Rev Neurosci 2002;3:102–114.
Celie PH, van Rossum-Fikkert SE, van Dijk W, et al. Nicotine and carbamylcholine binding to nicotinic acetylcholine receptors as studied in AChBP crystal structures. Neuron 2004;41:907–914.
Pereira EF, Hilmas C, Santos MD, et al. Unconventional ligands and modulators of nicotinic receptors. J Neurobiol 2002;53:479–500.
Mulle C, Lena C, Changeux JP. Potentiation of nicotinic receptor response by external calcium in rat central neurons. Neuron 1992;8:937–945.
Galzi JL, Bertrand S, Corringer PJ, et al. Identification of calcium binding sites that regulate potentiation of a neuronal nicotinic acetylcholine receptor. EMBO J 1996;15:5824–5832.
Pereira EF, Alkondon M, Reinhardt S, et al. Physostigmine and galanthamine: probes for a novel binding site on the alpha 4 beta 2 subtype of neuronal nicotinic acetylcholine receptors stably expressed in fibroblast cells. J Pharmacol Exp Ther 1994;70:768–778.
Zwart R, DeFilippi G, Broad LM, et al. 5-Hydroxyindole potentiates human α7 nicotinic receptor-mediated responses and enhances acetylcholine-induced glutamate release in cerebellar slices. Neuropharmacology 2002;43:374–384.
Kooyman AR, Van Hooft JA, Vijverberg HPM. 5-Hydroxyindole slows desensitization of 5-HT3 receptor-mediated ion current in N1E-115 neuroblastoma cells. Br J Pharmacol 1993;108:287–289.
Krause RM, Buisson B, Bertrand S, et al. Ivermectin: a positive allosteric effector of the α7 neuronal nicotinic acetylcholine receptor. Mol Pharmacol 1998;53:283–294.
Shan Q, Haddrill JL, Lynch JW. Ivermectin, an unconventional agonist of the glycine receptor chloride channel. J Biol Chem 2001;276:12556–12564.
Khakh BS, Proctor WR, Dunwiddle TV, et al. Allosteric control of gating and kinetics at P2X4 receptor channels. J Neurosci 1999;19:7289–7299.
Curtis L, Buisson B, Bertrand S, Bertrand D. Potentiation of human α4β2 neuronal nicotinic acetylcholine receptor by estradiol. Mol Pharmacol 2002;61:127–135.
Astles PC, Baker S, Boot JR, et al. Recent progress in the development of subtype selective nicotinic acetylcholine receptor ligands. Curr Drug Targets CNS Neurol Disord 2002;1:337–348.
Broad LM, Zwart R, Pearson KH, et al. Identification and pharmacological profile of a new class of selective nicotinic acetylcholine receptor potentiators. J Pharmacol Exp Ther 2006;318:1108–1117.
Clementi F, Cabrini D, Gotti C, Sher E. Pharmacological characterization of cholinergic receptors in a human neuroblastoma cell line. J Neurochem 1986;47:291–297.
Sher E, Chen Y, Sharples TJW, et al. Physiological roles of neuronal nicotinic receptor subtypes: new insights on the nicotinic modulation of neurotransmitter release, synaptic transmission and plasticity. Curr Top Med Chem 2004;4:283–297.
Dani JA. Overview of nicotinic receptors and their roles in the central nervous system. Biol Psychiatry 2001;49:166–174.
Court J, Martin-Ruiz C, Piggott M, et al. Nicotinic receptor abnormalities in Alzheimer’s disease. Biol Psychiatry 2001;49:175–184.
Quik M, Kulak JM. Nicotine and nicotinic receptors; relevance to Parkinson's disease. Neurotoxicology 2002;23:581–594.
Levin ED, Rezvani AH. Development of nicotinic drug therapy for cognitive disorders. Eur J Pharmacol 2000;393:141–146.
Buccafusco JJ, Letchworth SR, Bencherif M, Lippiello PM. Long-lasting cognitive improvement with nicotinic receptor agonists: mechanisms of pharmacokinetic-pharmacodynamic discordance. Trends Pharmacol Sci 2005;26:352–360.
Kem WR. The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21). Behav Brain Res 2000;113:169–181.
Lloyd GK, Williams M. Neuronal nicotinic acetylcholine receptors as novel drug targets. J Pharmacol Exp Ther 2000;2:461–467.
Maelicke A, Schrattenholz A, Samochocki M, et al. Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease. Behav Brain Res 2000;113:199–206.
Woodruff-Pak DS, Lander C, Geerts H. Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev 2002;8:405–426.
Samochocki M, Hoffle A, Fehrenbacher A, et al. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not muscarinic acetylchloline receptors. J Pharmacol Exp Ther 2003;305:1024–1036.
Moriguchi S, Marszalec W, Zhao X, et al. Mechanism of action of galantamine on N-methyl-d-aspartate receptors in rat cortical neurons. J Pharmacol Exp Ther 2004;310:933–942.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Science+Business Media, LLC
About this paper
Cite this paper
Sher, E. et al. (2008). Allosteric Potentiators of Neuronal Nicotinic Cholinergic Receptors: Potential Treatments for Neurodegenerative Disorders. In: Fisher, A., Memo, M., Stocchi, F., Hanin, I. (eds) Advances in Alzheimer’s and Parkinson’s Disease. Advances in Behavioral Biology, vol 57. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-72076-0_48
Download citation
DOI: https://doi.org/10.1007/978-0-387-72076-0_48
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-72074-6
Online ISBN: 978-0-387-72076-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)